

# ANTI-INFLAMMATORY PROPERTY OF RANITIDINE, A SPECIFIC H<sub>2</sub>-RECEPTOR ANTAGONIST

M. D. PATWARDHAN, M. P. MULEY AND M. S. MANEKAR

*Department of Pharmacology,  
Govt. Medical College, Miraj - 416 410 (MS)*

( Received on October 24, 1985 )

**Summary** : The effects of ranitidine (2 mg/kg, po) and phenylbutazone (100 mg/kg po) have been studied in different models of acute and chronic inflammation in rats. Ranitidine showed significant anti-inflammatory activity in the four models used. This observation supports the concept that histamine has a pro-inflammatory role that is mediated via stimulation of H<sub>2</sub>-receptors.

**Key words** : ranitidine

phenylbutazone

anti-inflammatory

## INTRODUCTION

Since Dale and Laidlaw's original observation in 1919 (4) that the local actions of histamine are similar to the inflammatory response, the possible involvement of histamine in inflammation is discussed extensively (12, 13). Pelczarska (11) reported that hypostamine, a histidine decarboxylase inhibitor reduced the inflammation and oedema associated with rat adjuvant arthritis. However, the 'classical' (i.e. H<sub>1</sub>) antihistamines did not affect the severity of rat adjuvant arthritis even at very high dose levels (2). The failure of the classical antihistamines to suppress many other inflammatory conditions has led investigators to suggest only a minor inflammatory role for histamine in acute inflammation (16). However, many actions of histamine which are resistant to the classical H<sub>1</sub> antihistaminics, have been shown to be blocked by the histamine H<sub>2</sub>-antagonists (3). Our earlier observations (10) have suggested the involvement of both H<sub>1</sub> and H<sub>2</sub> receptors in the local actions of histamine i.e. triple response. Hence it was thought worthwhile to study the role of H<sub>2</sub>-receptors in different models of acute and chronic inflammation using the new, specific H<sub>2</sub>-receptor antagonist, ranitidine.

## MATERIAL AND METHODS

Albino rats (Haffkine strain) of either sex (100-200 g) were used. For each set of

experiment, the rats were divided into three groups, each group containing at least six animals.

For the acute experiments, the rats were fasted for 18 hr, but water was allowed *ad-lib*. For the chronic experiments, the animals had free access to food and water throughout the seven days period. The drugs were given orally. Control animals received distilled water while the other two groups received solution of ranitidine hydrochloride (Glaxo Group Research Ltd; 2 mg/kg, po) and phenylbutazone (SG Pharmaceuticals; 100 mg/kg, po, as a suspension in 4% gum acacia). For the acute experiments, the animals received distilled water or drugs one hr prior to the injection of carrageenin, turpentine or formalin. Students 't' test was used for statistical analysis.

a) *Carrageenin-induced oedema* : The method of Winter, Risley and Nuss (15) was followed with slight modifications. Drugs or distilled water were given one hr before injecting carrageenin. 0.1 ml. of 2% carrageenin in 0.9% saline was then injected underneath the plantar aponeurosis of the left hind paw of the rat. The foot volume was measured by plethysmograph in the rats anaesthetised with ether, before and again 3 hr after carrageenin injection.

b) *Turpentine-induced arthritis* : Joint oedema was provoked by injection of 0.01 ml turpentine oil into the synovial cavity of the right knee joint with the help of a tuberculin syringe (7).

Knee joint lateral diameter was measured using vernier callipers measuring to 0.02 mm by the method described by Al-Haboubi *et al.* (1). The mean increase in joint diameter after 6 hr was compared in the two drug treated groups.

c) *Formalin-induced peritonitis* : The method adopted was that of Teotine *et al.* (14). The animals were treated with the respective drugs or normal saline and after one hr., all animals received 1 ml of 1.33% formalin (ip). After 6 hrs, the animals were sacrificed, abdomen cut open and the volume of exudate was measured.

d) *Cotton wool plect granuloma method* : The method of Meier, Schuler and De Saulles (9), as described by Finney and Somers (5) was adopted with slight modifications. A sterile cotton pellet weighing 10 mg was inserted, one in each flank. The test drugs were administered orally daily for seven days. The pellets were dissected out on the eighth day, dried in the oven till their weights remained, constant, and then weighed.

## RESULTS

Table I shows the effects of ranitidine and phenylbutazone in model of acute

inflammation (carrageenin-induced oedema, turpentine-induced arthritis and formaline-induced peritonitis). As is obvious, ranitidine decreased the formation of inflammatory exudate in all three models and the results were almost similar to those of phenylbutazone, though in the formalin-induced peritonitis it is slightly less effective.

A similar effect of ranitidine was also seen in the cotton pellet granuloma model which is a model of chronic inflammatory activity (Table I).

TABLE I : Effect of ranitidine and phenylbutazone in various models of inflammation in rats.

Model and parameter	Pre-treatment		
	Distilled water (controls)	Ranitidine 2 mg/kg, PO	Phenylbutazone 100 mg/kg, PO
a) Carrageenin pedal oedema (paw volume, ml)	4.79±0.19 (12)	2.50±0.19*** (9)	1.84±0.12*** (12)
b) Turpentine arthritis (Knee joint, lateral diameter, mm)	2.59±0.17 (10)	1.44±0.13* (8)	1.49±0.19* (8)
c) Formalin peritonitis (Volume of exudate, ml)	7.26±0.23 (12)	2.78±0.6*** (12)	1.22±0.10*** (11)
d) Cotton pellet granuloma (granuloma tissue, mg)	57.61±0.49 (8)	36.29±0.52*** (12)	36.72±0.35*** (16)

1. All values are mean ± S.E.M. Parentheses show number of rats in a group.
2. Value differs significantly from control. \* P<.05, \*\*\* P<.001.
3. Treatment was given once in (a), (b) & (c) and for 7 days in (d) See text for methodology and drug administration schedule.

## DISCUSSION

Folkow *et al.* (6) suggested the presence of two types of histamine receptors responsible for histamine induced vasodilatation. Only one of these could be effectively blocked by benadryl and the related compounds. This second type of receptor is labelled as H<sub>2</sub>- and the new H<sub>2</sub>-receptor blocking agents have been established to block those actions of histamine which were not blocked by the classical antihistaminics (3). New evidence implicates histamine as a possible mediator in a number of pathological conditions involving increase in vascular permeability and oedema. This action of histamine is

mediated through H<sub>2</sub>-receptors. Metiamide and cimetidine have been reported to suppress irradiation or thermal oedema (8). Al Haboubi and Zeitlin (1) have observed the anti-inflammatory activity of cimetidine in rat adjuvant arthritis model. Our previous observations (10) also suggest a role for H<sub>2</sub>-receptors in the local actions of histamine.

In concurrence with these reports, in the present study, ranitidine was found to significantly reduce the inflammatory response in different models of acute and chronic inflammation. This anti-inflammatory response was comparable to that of phenylbutazone in doses used, in all the models of inflammation used, except one i.e. formalin-induced peritonitis. However, we have not undertaken a systematic comparison in relative potencies. This report further supports the concept that histamine does have a proinflammatory role mediated via stimulation of H<sub>2</sub>-receptors.

The dose used in these experiments is higher than that is required to reduce gastric acid secretion. It would be worthwhile to find out whether low doses of ranitidine can produce synergistic effect with anti-inflammatory drugs. This would be particularly advantageous since H<sub>2</sub>-receptor antagonists would also counteract their limiting side effect i.e. peptic ulceration while adding to their therapeutic effect.

#### ACKNOWLEDGEMENTS

The authors wish to thank Glaxo Group Research Ltd., London, for the generous gift of ranitidine and SG Pharmaceuticals for their gift of phenylbutazone.

#### REFERENCES

1. Al-Haboubi, H.A. and I.J. Zeitlin. The actions of cimetidine and mepyramine in rat adjuvant arthritis. *Eur. J. Pharmac.*, **78**:75-85, 1982.
2. Barbieri, E.J., G. Victor Rossi and R.F. Orzechowski. Effect of histamine-epinephrine combinations on adjuvant arthritis in rats. *J. Pharmac. Sci.*, **62**:648, 1973.
3. Black, J.W., W.A.M. Duncan, C.J. Durant, C.R. Ganellin and E.M. Parson. Definition and antagonism of histamine H<sub>2</sub>-receptors. *Nature*, **236**:385, 1972.
4. Dale, H.H. and P.P. Laidlaw. Histamine Shock. *J. Physiol.*, **52**:355-390, 1919.
5. Finney, R.S.H. and G.R. Somers. The anti-inflammatory activity of glycerethinic acid and derivatives. *J. Pharm. Pharmac.*, **10**:613-620, 1958.
6. Folkow, B., K. Haeger and G. Kahlson. Observations on Reactive Hyperaemia as related to histamine, on drugs antagonizing vasodilatation induced by histamine and on vasodilator properties of adenosine-triphosphate. *Acta Physiol. Scand.*, **15**:264, 1948.
7. Hanson, J.M., J. Morley and C. Soria-Herrera. Anti-inflammatory property of 401 (MCD-Peptide), a peptide from the venom of the bee, *Apis mellifera*(L). *Br. J. Pharmac.*, **50**:383-392, 1974.
8. Joo, F.S.A. and E. Csanda. Metiamide treatment of brain in animals exposed to 90 yttrium irradiation. *J. Pharm. Pharmac.*, **28**:162, 1976.

9. Meier, R., W. Schuler and P. De Saulles. Zur Frage des Mechanismus der Hemmung des Bindegewebswachstums durch Cortisone. *Experientia*, 6:469-471, 1950.
10. Patwardhan, M.D., M.P. Muley and M.S. Manekar. Involvement of  $H_1$  - and  $H_2$  receptors in triple response to histamine in human volunteers. *Ind. J. Physiol. Pharmac.*, 28:335-337, 1984.
11. Pelczarska, A. Treatment of adjuvant arthritis in rats with histidine decarboxylase inhibitor, hypostamine. *J. Pharm. Pharmac.*, 21:692, 1969.
12. Rochae Silva, M. Histamine H and antihistamines. In: Handbook of Experimental Pharmacology. Berlin, Springer-Verlag, 18 (2). 1978.
13. Ryan, G.B. and G. Majno. Acute inflammation. *Am. J. Pathol.*, 86:185, 1977.
14. Teotino, U.M., P. Friz, A. Gandini and D-Della Bella. Antipyretic activity of Thioderivatives of 2, 3-Dihydro 4H-1, 3- Benzoxazin -4 - 1. Synthesis and pharmacological properties. *J. Med. Chem.*, 6:248, 1963.
15. Winter, C.A., E.A. Risley and G.W. Nuss. Carrageenin-induced oedema in hind paw of the rat as an assay for anti-inflammatory drugs. *Proc. Soc. Exp. Biol. (N.Y.)*, 111 : 544-547, 1962.
16. Youlten, L.J.F. Inflammatory mediators and vascular events, in : Handbook of Experimental Pharmacology. Editors Jane J. R. and S.H. Ferreira. Berlin, Springer Verlag. P 571, 1978.